Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Total RNA-seq of C2C12 myotubes treated with agrin or MuSK antibodies

ABSTRACT: Total RNA-seq was performed to investigate if MuSK antibody binding directly affects (NMJ) gene expression in muscle cells. C2C12 differentiated myotubes were treated for 16 hours with bivalent MuSK antibodies (activating MuSK signaling) or functionally monovalent MuSK antibodies (inhibiting agrin-induced MuSK signaling) derived from B-cell receptor sequences from a MuSK myasthenia gravis patient. The total RNA transcriptome was compared to treatment with agrin (the natural activator of MuSK) or a negative control antibody targeting a protein not present in myotubes.

ORGANISM(S): Mus musculus

PROVIDER: GSE316686 | GEO | 2026/01/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-nuclei sequencing of skeletal muscle reveals subsynaptic-specific transcripts involved in neuromuscular junction maintenance (snRNA-Seq)

Project description:The neuromuscular junction (NMJ) is the synapse formed between motor neurons and skeletal muscle fibers. Its stability relies on the continued expression of genes in a subset of myonuclei, called NMJ myonuclei. Here, we use single-nuclei RNA-sequencing (snRNA-seq) to identify numerous undescribed NMJ-specific transcripts. To elucidate how the NMJ transcriptome is regulated, we also performed snRNA-seq on sciatic nerve transected, botulinum toxin injected and Musk knockout muscles. These data show that NMJ gene expression is not only driven by agrin-Lrp4/MuSK signaling, but is also affected by electrical activity and trophic factors other than agrin. By selecting three previously undescribed NMJ genes Etv4, Lrtm1 and Pdzrn4, we further characterize novel contributors to NMJ stability and function. AAV-mediated overexpression and AAV-CRISPR/Cas9-mediated knockout show that Etv4 is sufficient to upregulate expression of ~50% of the NMJ genes in non-synaptic myonuclei, while muscle-specific knockout of Pdzrn4 induces NMJ fragmentation. Further investigation of Pdzrn4 revealed that it localizes to the Golgi apparatus and interacts with MuSK protein. Collectively, our data provide a rich resource of NMJ transcripts, highlight the importance of ETS transcription factors at the NMJ and suggest a novel pathway for NMJ post-translational modifications.

2025-02-10 | GSE267910 | GEO

Single-nuclei sequencing of skeletal muscle reveals subsynaptic-specific transcripts involved in neuromuscular junction maintenance (bulk RNA-Seq)

2025-02-10 | GSE267909 | GEO

Phosphoproteomics of MuSK Signaling

Project description:The development of the neuromuscular synapse depends on signaling processes which involve protein phosphorylation as a crucial regulatory event. The receptor tyrosine kinase MuSK is the key signaling molecule at the neuromuscular synapse whose activity is required for the formation of a mature and functional neuromuscular synapse. However, the signaling cascade downstream of MuSK and the regulation of the different components is still poorly understood. Here we present data from a quantitative phosphoproteomics approach to study MuSK-dependent processes. Muscle cells were stimulated with the heparansulfate proteoglycan agrin, which activates MuSK and downstream signaling events. To get an insight into the signaling dynamics we used three different time points (unstimulated, 15 min, 60 min and 4 hrs).

2014-06-05 | PXD000878 | Pride

Phosphoproteomics of MuSK Signaling

2014-06-05 | PXD000558 | Pride

Phosphoproteome Profiling of the Receptor Tyrosine Kinase MuSK Identifies Tyrosine Phosphorylation of Rab GTPases.

Project description:Muscle-specific receptor tyrosine kinase (MuSK) agonist antibodies were developed two decades ago to explore the benefits of receptor activation at the neuromuscular junction. Unlike agrin, the endogenous agonist of MuSK, MuSK agonist antibodies function independently of its co-receptor Lrp4. Recent reports suggest that MuSK agonist antibodies can delay the onset of muscle denervation in mouse models of amyotrophic lateral sclerosis (ALS). To get a deeper understanding of MuSK signaling, and potentially identify Lrp4-independent signaling downstream of MuSK activation, we performed phosphoproteome profiling of myotubes treated with each agonist. Our approach involved quantifying changes in site-specific phosphorylation in orthogonal dose response and time course experiments with each agonist using isobaric mass tags. We observed that both agonists elicited remarkably similar intracellular responses, as evidenced by highly correlating tyrosine phosphorylation on known MuSK signaling components and newly identified cytoskeletal and intracellular trafficking nodes. Among these was inducible phosphorylation on a conserved N-terminal phosphorylation site present on a family of endosomal Rab GTPases. We confirmed that suppression of MuSK signaling by a small molecule reduces Rab10 tyrosine phosphorylation. Importantly, Rab10 mutation at this site disrupts its association with adaptor molecules Mical1 and Mical3. Together these data provide an in depth characterization of the MuSK signaling pathway, describe two small molecule kinase inhibitors, and reveal a novel regulatory mechanism of small Rab GTPases that is poised to regulate intracellular trafficking downstream of receptor tyrosine kinase activation.

2020-06-04 | MSV000085547 | MassIVE

Proteomic profiling identifies ITIH3 as a biomarker for disease activity in myasthenia gravis

Project description:Myasthenia gravis (MG) is a chronic antibody-mediated autoimmune disease disrupting neuromuscular synaptic transmission. Antibodies (Abs) against the acetylcholine receptor (AChR) are detected in approximately 85% of patients. Here, we aimed to study the serum proteome of MG and to identify novel biomarkers reflecting disease activity.

2023-10-24 | PXD040786 | Pride

Single-nucleus transcriptomics and chromatin accessibility analysis of musk gland in Chinese forest musk deer

Project description:The Chinese forest musk deer (FMD; Moschus berezovskii) is an endangered artiodactyl mammal. Musk secreted by the musk gland of male FMD has extremely high economic and medicinal value. At present, little is known about the development of musk glands and the molecular mechanism of musk secretion. In the present research, using snRNA-seq and snATAC-seq association analysis performed on musk glands of forest musk deer, coupled with several bioinformatics analyses, the dynamic transcriptional cell atlas of musk gland development was revealed and the genes and transcription factors affecting musk secretion were determined. Based on uniform manifold approximation and projection (UMAP) analysis, we identified 12 cell types from musk glands, including two different acinar cells (clusters 0 and 10). In addition, the expression of core target genes and core transcription factors was verified by fluorescence in situ hybridization and immunohistochemistry. Combined with weighted gene co-expression network analysis (WGCNA), we obtained a deeper biological understanding of the relationship between core transcription factors, differentially expressed genes and musk secretion related pathways. This study lays a foundation for improving musk yield and meeting market demand. In the meantime, it also contributes to reducing the hunting and poaching of wild forest musk deer, protecting forest musk deer resources and maintaining ecological balance.

2023-08-31 | GSE182087 | GEO

Transcription profiling of thymus from myasthenia gravis patients

Project description:Identification of deregulated genes in the thymus of myasthenia gravis patients' subgroup.

2006-11-09 | E-MEXP-518 | biostudies-arrayexpress

Reemergence of pathogenic, autoantibody-producing B-cell clones in myasthenia gravis following B-cell depletion therapy.

Project description:Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the neuromuscular junction. Some patients with MG have pathogenic mAbs that recognize muscle-specific tyrosine kinase (MuSK). Patients respond well to CD20-mediated B-cell depletion therapy (BCDT); most achieve complete stable remission. However, relapse often occurs. To further understand the immunomechanisms underlying relapse we sought to study autoantibody-producing B-cells over the course of BCDT. We developed a monomeric fluorescently labelled antigen to enrich for MuSK-specific B-cells, which was validated with a novel Nalm6 cell line engineered to express a human MuSK autoantibody as B-cell receptor. We found that MuSK-specific B-cells are rare within the circulation (<3 per 10 million cells). From two MuSK-specific B-cells isolated from two distinct patients, we generated human recombinant MuSK mAbs. The autoantibodies originated from plasmablasts, used the IgG4 subclass, recognized the Ig1-like domain of MuSK and showed pathogenic capacity using an in vitro AChR clustering assay. Persistent clones of the mAbs were identified through B-cell repertoire tracing. Clonal variants of 2E6 were detected at several timepoints spanning more than five years months and reemerged after BCDT-mediated remission, appearing several months prior to relapse. These results indicate that a reservoir of rare pathogenic MuSK autoantibody-expressing B cell clones survive BCDT, then reemerge prior to manifestation of clinical relapse. This study provides both a mechanistic understanding of MuSK MG relapse and a valuable candidate biomarker for relapse prediction.

2022-11-07 | GSE215237 | GEO